Paul J. Scheel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Paul J. Scheel has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Kilic
Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland
3 shared publications Brittney Murray
Division of Cardiology, Department of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA
3 shared publicationsKatherine Giuliano
Johns Hopkins School of Medicine, Baltimore, MD
3 shared publicationsNisha A. Gilotra
Division of Cardiology, Department of Medicine, The Johns Hopkins University, Baltimore, Maryland, USA
3 shared publications- Nisha Aggarwal Gilotra
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 shared publications - Steven Hsu
Johns Hopkins University School of Medicine
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108741
Can Systemic Sarcoidosis and Genetic Cardiomyopathy Coexist?
- 3 June 2026
- Published by Elsevier in JACC: Case Reports
- p. 108741
Open AccessCan Systemic Sarcoidosis and Genetic Cardiomyopathy Coexist?
- 19 March 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70206
Cytomegalovirus “Blips” and Rates of Progression to Clinically Significant CMV in Cardiothoracic Transplant Recipients
Background: Guidelines suggest using a highly sensitive, quantitative nucleic acid test (QNAT) for CMV detection; however, there is no standardized threshold to guide preemptive therapy or initiation of CMV treatment. This study sought to characterize the incidence, time course, and management of CMV blips as well as the rate of progression to clinically significant CMV infection (CS‐CMVi) following a blip in cardiothoracic transplant recipients. Methods: This is a single‐center, retrospective study of heart and lung transplant recipients from January 2018 to August 2024. A CMV blip was defined as the first positive, detectable, and unquantifiable CMV‐QNAT. CS‐CMVi was defined as either viral load > 1000 IU/mL or initiation of treatment following a blip. Outcomes were assessed within 1 year of transplant. Results: Of the 196 patients included in the study, 58 patients (29.6%) had a CMV blip. A majority of patients (62.1%) were receiving CMV prophylaxis at the time of blip. The median time from transplant to CMV blip was 77.5 days and median time to CS‐CMVi, from blip, was 30 days. In the CMV high‐risk group (D+/R−), 71.4% (10/14) developed CS‐CMVi, compared with 21.4% (9/42) in the moderate risk group (R+) ( p = 0.001). Conclusion: In the first year following cardiothoracic transplantation, CMV blips are common occurrences. Patients at high‐risk for CMV were more likely to progress to CS‐CMVi than moderate risk patients. In the high‐risk population, this increased rate of progression gives further evidence that a CMV blip is a risk for the progression of CS‐CMVi in the absence of treatment.
- 19 March 2026
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (4) , e70206
Cytomegalovirus “Blips” and Rates of Progression to Clinically Significant CMV in Cardiothoracic Transplant Recipients
Background: Guidelines suggest using a highly sensitive, quantitative nucleic acid test (QNAT) for CMV detection; however, there is no standardized threshold to guide preemptive therapy or initiation of CMV treatment. This study sought to characterize the incidence, time course, and management of CMV blips as well as the rate of progression to clinically significant CMV infection (CS‐CMVi) following a blip in cardiothoracic transplant recipients. Methods: This is a single‐center, retrospective study of heart and lung transplant recipients from January 2018 to August 2024. A CMV blip was defined as the first positive, detectable, and unquantifiable CMV‐QNAT. CS‐CMVi was defined as either viral load > 1000 IU/mL or initiation of treatment following a blip. Outcomes were assessed within 1 year of transplant. Results: Of the 196 patients included in the study, 58 patients (29.6%) had a CMV blip. A majority of patients (62.1%) were receiving CMV prophylaxis at the time of blip. The median time from transplant to CMV blip was 77.5 days and median time to CS‐CMVi, from blip, was 30 days. In the CMV high‐risk group (D+/R−), 71.4% (10/14) developed CS‐CMVi, compared with 21.4% (9/42) in the moderate risk group (R+) ( p = 0.001). Conclusion: In the first year following cardiothoracic transplantation, CMV blips are common occurrences. Patients at high‐risk for CMV were more likely to progress to CS‐CMVi than moderate risk patients. In the high‐risk population, this increased rate of progression gives further evidence that a CMV blip is a risk for the progression of CS‐CMVi in the absence of treatment.
- 12 December 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (4) , 618-620
Less RV contractility but more afterload after LVAD: How two wrongs ache the right
- 12 December 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (4) , 618-620
Less RV contractility but more afterload after LVAD: How two wrongs ache the right
- 11 January 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 400, 131777
Role of genetics in inflammatory cardiomyopathy
- 11 January 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 400, 131777
Role of genetics in inflammatory cardiomyopathy
- Open Access
- 9 December 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3259
Management Strategies in Arrhythmogenic Cardiomyopathy across the Spectrum of Ventricular Involvement
Improved disease recognition through family screening and increased life expectancy with appropriate sudden cardiac death prevention has increased the burden of heart failure in arrhythmogenic cardiomyopathy (ACM). Heart failure management guidelines are well established but primarily focus on left ventricle function. A significant proportion of patients with ACM have predominant or isolated right ventricle (RV) dysfunction. Management of RV dysfunction in ACM lacks evidence but requires special considerations across the spectrum of heart failure regarding the initial diagnosis, subsequent management, monitoring for progression, and end-stage disease management. In this review, we discuss the unique aspects of heart failure management in ACM with a special focus on RV dysfunction.
- 9 December 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3259
Open AccessManagement Strategies in Arrhythmogenic Cardiomyopathy across the Spectrum of Ventricular Involvement
Improved disease recognition through family screening and increased life expectancy with appropriate sudden cardiac death prevention has increased the burden of heart failure in arrhythmogenic cardiomyopathy (ACM). Heart failure management guidelines are well established but primarily focus on left ventricle function. A significant proportion of patients with ACM have predominant or isolated right ventricle (RV) dysfunction. Management of RV dysfunction in ACM lacks evidence but requires special considerations across the spectrum of heart failure regarding the initial diagnosis, subsequent management, monitoring for progression, and end-stage disease management. In this review, we discuss the unique aspects of heart failure management in ACM with a special focus on RV dysfunction.
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S115
Heart Transplantation Strategies In Arrhythmogenic Right Ventricular Cardiomyopathy: The Johns Hopkins Experience
- 28 April 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (5) , S115
Heart Transplantation Strategies In Arrhythmogenic Right Ventricular Cardiomyopathy: The Johns Hopkins Experience
- Open Access
- 24 December 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (2) , 1008-1017
Heart Transplantation Strategies in Arrhythmogenic Right Ventricular Cardiomyopathy: A Tertiary ARVC Centre Experience
Aims End-stage heart failure necessitating evaluation for heart transplantation is increasingly recognized in arrhythmogenic right ventricular cardiomyopathy (ARVC). These patients present unique challenges in pre-transplant and peri-transplant management given their predominantly right ventricular (RV) failure and propensity for ventricular arrhythmias. We sought to utilize a tertiary ARVC referral and heart transplant centre experience to describe management of a series of patients with ARVC undergoing heart transplantation at our centre. Methods and results We queried the Johns Hopkins ARVC Registry for all patients who underwent heart transplantation and further studied the subset undergoing transplantation at the Johns Hopkins Hospital. Patient demographics, clinical characteristics, and pre-transplant clinical course were obtained from the registry and electronic medical records. Of the 532 patients in the ARVC Registry, 63 (12%) underwent heart transplantation. Nine (six male) of these patients both had known ARVC prior to transplant and were transplanted at Johns Hopkins Hospital between 2006 and 2020 at a mean age of 42 ± 14 years old. Pathogenic ARVC genetic variants were identified in six (67%) patients, all of whom had variants in the plakophilin-2 (PKP2) gene. RV failure was universal with median right atrial to pulmonary capillary wedge pressure (RA/PCWP) ratio of 1.4 [interquartile range (IQR) 1.2–1.5] and median right ventricular stroke work index (RVSWI) of 0 g·m/m2/beat (IQR 0–0.3). Six had a history of catheter ablation for ventricular arrhythmia with five of the six having at least three ablations. Transplant evaluation was initiated an average of 344 ± 407 days after first developing heart failure symptoms. The most common bridge to transplant support included inotropes (n = 3) and extracorporeal membrane oxygenation (ECMO) (n = 2). Contraindication to inotropes or mechanical support was common due to ventricular arrhythmia and RV predominant cardiomyopathy. Conclusions Heart transplantation is a curative treatment for ARVC, but due to frequent ventricular arrhythmias and RV predominant pathology, patients require unique considerations in regard to timing of evaluation, haemodynamic support options, and wait listing qualification.
- 24 December 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (2) , 1008-1017
Open AccessHeart Transplantation Strategies in Arrhythmogenic Right Ventricular Cardiomyopathy: A Tertiary ARVC Centre Experience
Aims End-stage heart failure necessitating evaluation for heart transplantation is increasingly recognized in arrhythmogenic right ventricular cardiomyopathy (ARVC). These patients present unique challenges in pre-transplant and peri-transplant management given their predominantly right ventricular (RV) failure and propensity for ventricular arrhythmias. We sought to utilize a tertiary ARVC referral and heart transplant centre experience to describe management of a series of patients with ARVC undergoing heart transplantation at our centre. Methods and results We queried the Johns Hopkins ARVC Registry for all patients who underwent heart transplantation and further studied the subset undergoing transplantation at the Johns Hopkins Hospital. Patient demographics, clinical characteristics, and pre-transplant clinical course were obtained from the registry and electronic medical records. Of the 532 patients in the ARVC Registry, 63 (12%) underwent heart transplantation. Nine (six male) of these patients both had known ARVC prior to transplant and were transplanted at Johns Hopkins Hospital between 2006 and 2020 at a mean age of 42 ± 14 years old. Pathogenic ARVC genetic variants were identified in six (67%) patients, all of whom had variants in the plakophilin-2 (PKP2) gene. RV failure was universal with median right atrial to pulmonary capillary wedge pressure (RA/PCWP) ratio of 1.4 [interquartile range (IQR) 1.2–1.5] and median right ventricular stroke work index (RVSWI) of 0 g·m/m2/beat (IQR 0–0.3). Six had a history of catheter ablation for ventricular arrhythmia with five of the six having at least three ablations. Transplant evaluation was initiated an average of 344 ± 407 days after first developing heart failure symptoms. The most common bridge to transplant support included inotropes (n = 3) and extracorporeal membrane oxygenation (ECMO) (n = 2). Contraindication to inotropes or mechanical support was common due to ventricular arrhythmia and RV predominant cardiomyopathy. Conclusions Heart transplantation is a curative treatment for ARVC, but due to frequent ventricular arrhythmias and RV predominant pathology, patients require unique considerations in regard to timing of evaluation, haemodynamic support options, and wait listing qualification.